Get the Stockscreener App
54.80
1.03%
-0.57
After Hours:
54.60
-0.20
-0.36%
Halozyme Therapeutics Inc stock is traded at $54.80, with a volume of 907.93K.
It is down -1.03% in the last 24 hours and up +12.76% over the past month.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
See More
Previous Close:
$55.37
Open:
$55.66
24h Volume:
907.93K
Relative Volume:
0.57
Market Cap:
$6.97B
Revenue:
$947.36M
Net Income/Loss:
$392.47M
P/E Ratio:
18.15
EPS:
3.02
Net Cash Flow:
$392.71M
1W Performance:
+3.79%
1M Performance:
+12.76%
6M Performance:
+0.09%
1Y Performance:
+52.05%
1-Day Range:
$54.77
$55.73
1-Week Range:
$52.23
$55.79
52-Week Range:
$33.15
$65.53
Halozyme Therapeutics Inc Stock (HALO) Company Profile
Name
Halozyme Therapeutics Inc
Sector
Industry
Phone
(858) 794-8889
Address
12390 EL CAMINO REAL, SAN DIEGO, CA
Compare HALO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
54.80 | 6.97B | 947.36M | 392.47M | 392.71M | 3.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-19-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-07-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-29-24 | Initiated | TD Cowen | Outperform |
| Jul-24-23 | Downgrade | Goldman | Buy → Neutral |
| Jul-24-23 | Initiated | H.C. Wainwright | Buy |
| May-10-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-27-23 | Resumed | Berenberg | Buy |
| Mar-16-23 | Downgrade | SVB Securities | Outperform → Market Perform |
| Dec-21-22 | Resumed | Morgan Stanley | Overweight |
| Nov-28-22 | Initiated | Wells Fargo | Overweight |
| Sep-09-22 | Initiated | Morgan Stanley | Overweight |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Jun-14-21 | Initiated | Evercore ISI | Outperform |
| May-17-21 | Initiated | SVB Leerink | Outperform |
| May-11-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-21-21 | Reiterated | The Benchmark Company | Buy |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Jul-01-20 | Initiated | The Benchmark Company | Buy |
| Feb-05-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-09-20 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-08-20 | Initiated | Goldman | Buy |
| Nov-05-19 | Upgrade | Barclays | Underweight → Equal Weight |
| Oct-19-18 | Resumed | Piper Jaffray | Neutral |
| May-11-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-24-18 | Initiated | Goldman | Neutral |
| Oct-16-17 | Reiterated | Piper Jaffray | Overweight |
| Jan-06-17 | Downgrade | Citigroup | Buy → Neutral |
| Nov-03-16 | Initiated | Deutsche Bank | Buy |
| Dec-04-15 | Initiated | Wells Fargo | Outperform |
| Nov-18-15 | Initiated | Citigroup | Buy |
| Sep-22-15 | Initiated | Barclays | Overweight |
| Jun-22-15 | Reiterated | JP Morgan | Overweight |
| Mar-03-15 | Reiterated | UBS | Buy |
| Feb-18-15 | Reiterated | MLV & Co | Buy |
| Jan-08-15 | Reiterated | MLV & Co | Buy |
View All
Halozyme Therapeutics Inc Stock (HALO) Latest News
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Sees Large Growth in Short Interest - MarketBeat
Empirical Asset Management LLC Invests $1.09 Million in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Bernzott Capital Advisors Purchases New Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Outlook Wealth Advisors LLC Makes New Investment in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Converting IV-drip Medications into Shots -January 16, 2025 at 12:29 pm EST - Marketscreener.com
(HALO) Technical Data - Stock Traders Daily
Research Analysts Offer Predictions for HALO FY2025 Earnings - MarketBeat
Zacks Industry Outlook Highlights Incyte, BioMarin, Exelixis, Halozyme and Blueprint Medicines - Yahoo Finance
Wells Fargo & Company Has Lowered Expectations for Halozyme Therapeutics (NASDAQ:HALO) Stock Price - Defense World
5 Biotech Stocks Worth Adding to Your Portfolio in 2025 - Zacks Investment Research
Q1 Earnings Forecast for HALO Issued By Leerink Partnrs - MarketBeat
Analyst Expectations For Halozyme Therapeutics's Future - Benzinga
Halozyme Therapeutics (NASDAQ:HALO) Price Target Cut to $57.00 by Analysts at Wells Fargo & Company - MarketBeat
Analysts Set Halozyme Therapeutics, Inc. (NASDAQ:HALO) Price Target at $61.44 - MarketBeat
Piper Sandler Increases Halozyme Therapeutics (NASDAQ:HALO) Price Target to $53.00 - Defense World
HC Wainwright Forecasts Strong Price Appreciation for Halozyme Therapeutics (NASDAQ:HALO) Stock - Defense World
HALO Raises 2025 Financial Guidance, Keeps 2024 View, Stock Up - MSN
Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why - MSN
Halozyme raises 2025 guidance, announces $250M stock buyback - MSN
Halozyme Therapeutics (NASDAQ:HALO) Price Target Raised to $53.00 - MarketBeat
Q3 EPS Estimate for Halozyme Therapeutics Lifted by Analyst - MarketBeat
Are Options Traders Betting on a Big Move in Halozyme (HALO) Stock? - MSN
Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today - Yahoo Finance
Q1 EPS Forecast for Halozyme Therapeutics Raised by Analyst - MarketBeat
Earnings call transcript: Halozyme Q3 2024 boosts guidance amid strong growth - Investing.com India
First Hawaiian Bank Purchases 20,700 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Everence Capital Management Inc. Purchases New Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - Defense World
Halozyme Therapeutics (NASDAQ:HALO) Shares Gap UpTime to Buy? - MarketBeat
Halozyme Announces Takeda Received Regulatory Approval for HYQVIA® 10% Subcutaneous Injection Set with ENHANZE® in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia - Kilgore News Herald
Halozyme Therapeutics (NASDAQ:HALO) Updates FY 2025 Earnings Guidance - MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) Updates FY 2024 Earnings Guidance - MarketBeat
Halozyme Therapeutics, Inc. Raises Earnings Guidance for the Full Year 2025 -January 08, 2025 at 07:00 am EST - Marketscreener.com
Halozyme Therapeutics (NASDAQ:HALO) Updates FY24 Earnings Guidance - MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) Releases FY25 Earnings Guidance - MarketBeat
Halozyme Therapeutics, Inc. Reiterates Earnings Guidance for the Full Year 2024 - Marketscreener.com
Halozyme Reiterates 2024 Financial Guidance and Raises 2025 and Multi-Year Financial Guidance - PR Newswire
Halozyme Therapeutics director Jeffrey Henderson sells $500,060 in stock - Investing.com India
Insider Sell: Jeffrey Henderson Sells 10,000 Shares of Halozyme Therapeutics Inc (HALO) - GuruFocus.com
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Jeffrey William Henderson Sells 10,000 Shares - MarketBeat
The Zacks Rank Explained: How to Find Strong Buy Medical Stocks - Yahoo Finance
Zacks.com featured highlights include Leidos, Amazon.com, Halozyme Therapeutics and BioMarin Pharmaceutical - Yahoo Finance
Halozyme to Host Investor Conference Call to Provide Updated 2025 Financial Guidance - The Malaysian Reserve
Halozyme Therapeutics (HALO) Shares Cross Above 200 DMA - Nasdaq
Halozyme: 'Accidental' Business Model Has Exciting Upside Opportunities In 2025 - Seeking Alpha
Halozyme: Recent Approvals Alter My Appetite (NASDAQ:HALO) - Seeking Alpha
FDA Approves BMS’ Opdivo Qvantig with Halozyme’s ENHANZE Technology - Contract Pharma
Halozyme Therapeutics' (HALO) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Halozyme Therapeutics Inc Stock (HALO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.65%
4.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):